Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T13:45:20.932Z.
Calculation as of: 2026-10-06T13:45:20.932Z.
Quote observation: 2026-10-06T13:43:53.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: bd475241593d5c58f7737f650220a879a7f67ee05652ed27eb0102460b642cb0
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Acrivon Therapeutics, Inc. Common Stock
Market Cap
$87.10M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$84.44M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$83.97M
EV/EBIT Ratio
N/A
TTM Avg
10.94x
3Y Avg
10.94x
5Y Avg
10.94x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Acrivon Therapeutics, Inc. Common Stock (ACRV) | $87.10M | N/A | N/A | N/A | N/A |
| Citius Oncology, Inc. (CTOR)vs › | $85.53M | N/A | N/A | N/A | N/A |
| Humacyte, Inc. (HUMA)vs › | $84.52M | N/A | N/A | N/A | N/A |
| Cognition Therapeutics, Inc. (CGTX)vs › | $84.44M | N/A | N/A | N/A | N/A |
| CareCloud, Inc. (CCLD)vs › | $87.11M | 13.59x | 11.03x | 8.69x | 166.50x |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $83.97M | N/A | 10.94x | 10.94x | 10.94x |
| LENSAR Inc (LNSR)vs › | $81.80M | N/A | N/A | N/A | N/A |
| Cardiff Oncology, Inc. (CRDF)vs › | $88.63M | N/A | N/A | N/A | N/A |
| Conexeu Sciences Inc. (CNXU)vs › | $88.84M | N/A | N/A | N/A | N/A |
| ImmuCell Corporation (ICCC)vs › | $89.11M | 23.98x | 34.08x | 34.41x | 73.74x |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
